Cytomegalovirus antigenemia test (CMV pp65) is essential to diagnose and monitor CMV infection in immunocompromised patients, such as those with hematological or solid organ transplantation or AIDS. [1] [2] [3] [4] It is also useful to diagnose primary CMV infection in a non-transplant setting. 5 We report a case using CMV antigenemia test to diagnose and monitor primary CMV infection in an otherwise healthy stem cell donor.
A 21-year-old man was evaluated as a stem cell donor for his fully HLA-matched brother. A week earlier, he reported the onset of a low-grade fever and a sore throat that resolved without medical care. Physical examination was normal whereas laboratory tests revealed a mild atypical lymphocytosis (50%), eosinophilia (6%), basophilia (2%), neutropenia (35% of a total WBC of 5000/l), and elevations of ALT (78 mg/dl) and LDH (684 mg/dl). Next day serological tests were performed, which revealed moderate positive anti-CMV IgM (ELISA OD ratio 2.70), but negative anti-CMV IgG and anti-toxoplasma antibodies. The panel of antibodies against Epstein-Barr virus suggested past infection. Therefore, a diagnosis of primary CMV infection was made and his stem cell donation postponed.
His overall wellbeing led us to follow him without anti-CMV therapy while performing serial CMV antigenemia tests to guide the timing of stem cell harvest. Nine days after the onset of clinical manifestations, the CMV antigenemia test had six positive cells per million WBCs. By day 13, CMV antigenemia remained positive (four cells/10 6 WBC), as did neutropenia (35%) and atypical lymphocytes (resolved lymphocytosis). He also developed monocytosis (20%) and anemia (hemoglobin 13.3 mg/dl and hematocrit 37.7%).
By day 35, CMV antigenemia became negative, whereas anti-CMV IgG converted (OD ratio 3.78, moderately positive) and anti-CMV IgM titer increased (OD ratio 8.30). His anemia, atypical lymphocytes and elevated ALT all resolved and the monocytosis improved (13%). At this point, collection of his peripheral blood stem cells proceeded upon pretreatment with filgrastim (6 g/kg subcutaneously twice daily for 3 days), yielding 17.9 ϫ 10 6 CD34
+ cells in one leukapharesis. This case illustrates that, in a transplant setting or otherwise where primary CMV infection is in the differential diagnosis, a rapid (4 h) CMV antigenemia test may prove to be useful. CMV IgM antibody alone, particularly when weakly positive, is not sufficient to diagnose primary CMV infection. Thus, a complementary CMV antigenemia test may be helpful to confirm the diagnosis, as well as to date the infection. This test is sensitive (at least 90%), specific (96%), and can be positive as early as 3 days after the onset of symptoms. 5 This case also provides insight into the natural course of primary CMV infection in a normal host.
